🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 13 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 16/06/2011 | 46,38 | 46,50 | 45,20 | 45,59 | -1,79% | 2,80% | 1.899.200 |
| 15/06/2011 | 46,65 | 47,44 | 45,97 | 46,42 | -0,77% | 3,15% | 2.941.800 |
| 14/06/2011 | 47,44 | 47,61 | 46,60 | 46,78 | -0,97% | 2,13% | 2.287.000 |
| 13/06/2011 | 48,24 | 48,67 | 47,20 | 47,24 | -1,99% | 3,05% | 2.111.600 |
| 10/06/2011 | 48,01 | 49,01 | 47,48 | 48,20 | +0,27% | 3,19% | 3.303.500 |
| 09/06/2011 | 50,25 | 50,50 | 46,15 | 48,07 | -9,54% | 8,66% | 12.297.400 |
| 08/06/2011 | 54,09 | 54,23 | 52,96 | 53,14 | -1,90% | 2,35% | 1.201.600 |
| 07/06/2011 | 54,27 | 54,93 | 53,83 | 54,17 | -0,37% | 2,03% | 995.900 |
| 06/06/2011 | 54,36 | 54,89 | 53,80 | 54,37 | -0,71% | 2,01% | 1.300.100 |
| 03/06/2011 | 53,65 | 55,42 | 53,40 | 54,76 | +0,48% | 3,77% | 2.152.200 |
| 02/06/2011 | 52,90 | 54,68 | 52,88 | 54,50 | +2,79% | 3,40% | 2.058.900 |
| 01/06/2011 | 54,48 | 54,69 | 53,01 | 53,02 | -1,80% | 3,08% | 1.379.500 |
| 31/05/2011 | 54,33 | 54,68 | 52,98 | 53,99 | +0,84% | 3,13% | 1.810.200 |
| 27/05/2011 | 54,01 | 54,46 | 53,38 | 53,54 | -1,36% | 2,00% | 1.328.800 |
| 26/05/2011 | 55,17 | 55,47 | 52,85 | 54,28 | -2,32% | 4,75% | 2.560.900 |
| 25/05/2011 | 56,32 | 56,64 | 55,06 | 55,57 | -1,23% | 2,81% | 2.623.900 |
| 24/05/2011 | 55,81 | 56,47 | 55,55 | 56,26 | +0,81% | 1,65% | 2.279.300 |
| 23/05/2011 | 55,05 | 55,83 | 53,55 | 55,81 | +1,47% | 4,14% | 3.700.000 |
| 20/05/2011 | 54,51 | 55,61 | 54,15 | 55,00 | +0,38% | 2,68% | 2.330.400 |
| 19/05/2011 | 55,89 | 56,00 | 54,16 | 54,79 | -1,14% | 3,29% | 3.084.800 |
| 18/05/2011 | 56,68 | 56,68 | 55,24 | 55,42 | -1,93% | 2,54% | 2.780.700 |
| 17/05/2011 | 57,15 | 57,86 | 56,12 | 56,51 | -1,33% | 3,04% | 3.299.300 |
| 16/05/2011 | 55,87 | 57,86 | 55,41 | 57,27 | -0,37% | 4,39% | 2.404.200 |
| 13/05/2011 | 58,25 | 58,36 | 57,03 | 57,48 | -0,91% | 2,28% | 1.018.000 |
| 12/05/2011 | 56,15 | 58,87 | 55,68 | 58,01 | +3,13% | 5,68% | 2.100.000 |
| 11/05/2011 | 56,74 | 57,00 | 55,31 | 56,25 | -1,40% | 2,98% | 1.800.000 |
| 10/05/2011 | 57,82 | 57,89 | 56,12 | 57,05 | -1,04% | 3,06% | 2.169.700 |
| 09/05/2011 | 55,38 | 57,94 | 55,22 | 57,65 | +5,70% | 4,91% | 2.790.400 |
| 06/05/2011 | 53,82 | 55,38 | 53,55 | 54,54 | +2,54% | 3,40% | 2.001.900 |
| 05/05/2011 | 54,87 | 55,10 | 52,95 | 53,19 | -3,83% | 3,92% | 2.300.000 |